Brainose Technologies

Nasal Delivery of Cannabis-derived Therapeutics

Health Tech & Life Sciences
Non Active, Mar 2019 ceased to operate

Company Overview

Snapshot

Founded in January 2017 by Yossi Bornstein and Ofer Spottheim, Brainose Technologies operated with 1–10 employees. The company ceased operations in March 2019.

Business overview

Brainose Technologies specializes in developing a nose-to-brain delivery system for cannabis-derived therapeutics, targeting central nervous system (CNS) indications. The company focused on creating pharmaceutical-grade cannabinoid-based therapies, specifically for pain management, aiming for FDA and CE approval in the U.S. and Europe. Its core technology is designed to provide precise and reproducible dose delivery, serving the healthcare and life sciences sectors, particularly patients requiring medical cannabis and drug delivery solutions.

Company Intelligence Q&A

What is Brainose Technologies' primary focus?
Brainose Technologies focuses on developing a nose-to-brain delivery system for cannabis-derived therapeutics, primarily for central nervous system (CNS) indications.
When was Brainose Technologies founded?
Brainose Technologies was founded in January 2017.
Who are the founders of Brainose Technologies?
Brainose Technologies was co-founded by Yossi Bornstein and Ofer Spottheim.
What markets did Brainose Technologies aim to serve?
Brainose Technologies aimed to serve markets in the United States and Europe, focusing on obtaining FDA and CE approval for its therapies.
What was the operational status of Brainose Technologies?
Brainose Technologies ceased to operate in March 2019.

External links